High-Throughput Monitoring of Hydroxychloroquine and Chloroquine in Patients Diagnosed with COVID-19 Using Luxon-MS/MS

The current COVID-19 pandemic we are experiencing is being studied by scientists and clinicians around the world. From its means of proliferation and contagion, to the potential treatments that could defeat it, this new coronavirus is under a lot of scrutiny.

Trials are undergoing to test the effects of hydroxychloroquine/chloroquine on patients with COVID-19

A number of clinical trials are currently ongoing, such as the use of colchicine, remdesivir, or chloroquine/hydroxychloroquine to treat COVID-19 diagnosed patients. Click here for all of the clinical trials.

Chloroquine and hydroxychloroquine have displayed the ability to inhibit the replication of multiple coronaviruses in vitro. Publications support the hypothesis that both chloroquine and hydroxychloroquine could improve the clinical outcome of patients diagnosed with coronavirus disease 2019 (COVID-19). Hydroxychloroquine appears to be safer and more potent in inhibiting the causative virus, severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), in vitro. The numerous molecular mechanisms by which they can achieve such results remain to be further explored.  Early reports of its use in vivo have been promising.

However, no randomized clinical trials have been conducted to inform clinical guidance on the use, dosing, and duration of chloroquine/hydroxychloroquine for prophylaxis or treatment of COVID-19. The potential unprescribed use of chloroquine and hydroxychloroquine is alarming, since it may lead to irreversible vision loss. Although it may appear safe at low doses, chloroquine and hydroxychloroquine retinopathy is most influenced by daily dose, length of use, and cumulative dose.

The kinetics of chloroquine metabolism are complex, as its half-life increases with increasing intake.

Our goal for this application note is to present a Therapeutic Drug Monitoring method that allows the quantitation of Chloroquine and Hydroxychloroquine in blood in less than 8 seconds per sample.  This high-throughput method enables numerous patients to be continuously monitored, thus preventing irreversible vision loss or impairing effects. Sample preparation is reduced to the minimum to keep up with the analysis throughput.

You may find the application notes here:

On a Sciex 5500 MS

On a Shimadzu 8060 MS

Last news and events

Subscribe to our mailing list

* indicates required